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A B S T R A C T
Budesonide/formoterol as single inhaler was developed for treating asthma patients who are not adequately con-
trolled on glucocorticoides alone. The aim of this study was to evaluate efficacy, safety and patient/physician satisfaction
of budesonide/formoterol therapy.Total of 268 asthma patients (120 men, mean age 38,8 ± 37,2 years, and 148 women,
mean age 42,2 ± 32 years) were included in the study. All patients received budesonide/formoterol bid (640 mcg of bude-
sonide and 18 mcg of formoterol daily) during run-in period for three weeks. Patients were followed during 14 weeks at 5
visits.At each visit lung function (FEV1 and PEF) was measured,presence of side affects was recorded and questionnaire
was given to patients and physicians to estimate the level of satisfaction with budesonide/formoterol therapy (1 very un-
satisfied to 5 very satisfied). Significant improvement was noticed in FEV1, from 76,25% of predicted value to 86,94%
(p<0,01); and in PEF from 380,84 L/min to 442,29 L/min (p<0,01) in all patients. At the end of the study patients’ satis-
faction with budesonide/formeterol therapy was significantly improved comparing with satisfaction with previously
taken therapy,in average grade, from 2,94 to 4,56 (p<0,01),and similar results were noticed with physicians’ satisfac-
tion, from 2,60 to 4,41 (p<0,01). Budesonide/formoterol in single inhaler, significantly improved lung function in pa-
tients with asthma.
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Introduction
Asthma is a chronic inflammatory disease of the air-
ways. The underlying inflammation leads to hyperres-
ponsivnes of the airways which results in reversible
bronchial obstruction. Fluctuations in symptoms and
airway inflammation are major characteristics of asth-
ma. Asthma can not be cured, although it is a disease
that can be managed effectively with combination of trig-
ger avoidance, education and pharmacotherapy1. Effec-
tive control of asthma symptoms and maintenance of op-
timal lung function are crucial for the long – term mana-
gement of patients with asthma. Asthma control is de-
fined to achieve and maintain control of the symptoms
and best possible lung function, and at the same time to
prevent worsening and exacerbations of asthma and to
achieve best possible quality of life2,3. Despite available
and precise treatment guidelines, in many patients asth-
ma is under treated and control of the diseases is not
achieved4.
Current asthma treatment guidelines recommend a
stepwise approach to the treatment of asthma in adults
based on the severity of the disease2,3. Inhaled cortico-
steroids (ICS) are accepted for the first – line manage-
ment of moderate to severe persistent asthma, but do not
always provide sufficient control of the disease in all pa-
tients. For patients who are not well controlled by ICS
alone, as first line add – on treatment are recommended
long – acting b2 – agonists (LABA), like formoterol and
salmeterol. First study that gave rational for adding
LABA to ICS as first – line option was published by
Greening and colleagues and showed that adding LABA
to ICS is more effective than increasing the dose of ICS
in treating asthma patients5. Further studies, using bu-
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desonide and formoterol confirmed that adding LABA to
low dose of ICS in patients previously treated with ICS is
superior in improving lung function compared to two –
folds or even four – folds increase in the dose of ICS6,7.
Price and colleagues showed that adding formoterol to
low dose budesonide results in faster and more effective
asthma control than budesonide alone in patients with
mild asthma8.
However, there is a need to simplify the asthma treat-
ment, particularly when patients are using more than
one medication for the treatment of their disease. Pa-
tients would prefer as less as possible medications to con-
trol their disease, and would prefer as less as possible in-
halers for drug delivery9. In the last years, two fixed
combination of inhaled corticosteroid and long – acting
b2 – agonists were developed: combination of fluticasone
propionate and salmeterol (SeretideTM/ AdvairTM, Glaxo-
SmithKline) and combination of budesonide and for-
moterol (Symbicort®, AstraZeneca).
Since then, several studies established efficacy and
safety of budesonide and formoterol fixed combination in
the treatment of asthma in adults, as well as in chil-
dren10–12.
The aim of this 14 – week open – labeled study was to
estimate efficacy and safety of fixed budesonide/formo-
terol combination (Symbicort® Turbuhaler®, AstraZe-
neca) in patients with persistent asthma. Primary end
point of this study was improvement in lung function,
and secondary end points were to estimate patients’ and
physicians’ satisfaction with the budesonide/formoterol
treatment.
Methods
Patients
Male and female asthma patients aged = 11 years
were eligible for the inclusion in the study in if:
1) They were newly diagnosed asthma patient with
moderate to severe persistent asthma according to GINA
guidelines (2) previously not treated; or
2) They were using inhaled corticosteroids at daily
dose  400 mcg of budesonide propionate or equivalent
daily; or
3) They were using ICS and LABA in separate inhal-
ers; or
4) They were inadequately controlled on fixed flu-
ticason/salmeterol combination; or
5) They were inadequately treated with ICS and short
– acting b2 – agonist as needed; or
6) They were using oral corticosteroids for more than
10 days in the last three months; or
7) They were hospitalized due to asthma in the last 12
months.
The study was conducted in accordance with the Dec-
laration of Helsinki. The local ethics committees ap-
proved the study protocol. All patients gave written in-
formed consent before entering the study.
Study Design
This was open – labeled, controlled study conducted
at 10 outpatient centers in Croatia. At the initial visit pa-
tient underwent physical examination and their medical
histories were recorded. Patients then entered a 3 – week
run – in period during which they received budesonide/
formoterol (Symbicort Turbuhaler®, AstraZeneca) 160/
4.5 mcg two inhalations twice daily plus short – acting b2
– agonist salbutamol (Ventolin) as needed. Patients re-
turned to the centers for follow – up visits after 3, 6, 10
and 14 weeks of the treatment.
Assessments
At each visit lung function was tested by spirometry
(Erlich Jaeger, Master Lab Body) in accordance to Euro-
pean Respiratory Society guidelines (13). The highest
value for FEV1 from at least three acceptable attempts
was recorded with no reliever medication being used
within the 6 hours before the performance of the lung
function tests.
At each visit also peak expiratory flow (PEF) was also
recorded, again using the highest value from at least
three acceptable attempts with no reliever medications
being used within the 6 hours.
At each visit patients also recorded symptoms (cough,
dyspnea, chest tightness, night awakening due to asthma)
in a period of time from the last visit.
At each visit patient and physician graded their satis-
faction with therapy: from very unsatisfied (grade 1), un-
satisfied (grade 2), moderately satisfied (grade 3), satis-
fied (grade 4) and very satisfied (grade 5).
Patients were recording their symptoms on daily base
and symptoms were graded as mild, moderate and sever,
Safety was assessed by recording spontaneously re-
ported adverse events or in response to question asked by
the investigator at each visit.
The budesonide/formoterol dose 160/4.5 two inhala-
tions bid was reduced by the physicians to one inhalation
bid if there was normal lung function measured and no
symptoms or need for reliever therapy occurred since the
last visit.
Statistical analysis
The data were presented in absolute and relative fre-
quencies of various answers. Changes from baseline were
analyzed by analysis of variance (ANOVA). The results
considered statistically significant for p values less then
0.05. Statistical analyses were performed using the SPSS
software.
Results
A total of 268 patients were enrolled in the study with
slight female predominance (148 females, 115 males)
with mean age 40.8 years. Only 16% of patients were
newly diagnosed. More than half of patients (145 pa-
tients, 54.2%) had every day symptoms. All patients had
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persistent asthma, with majority of them (80%, 214 pa-
tients) had moderate persistent asthma. Patients were
receiving various previous medications: 39% were not
well controlled on fluticasone/salmeterol, 11% of patients
were using fluticasone alone, 12% of patients were using
budesonide alone and 7% of patients were using sal-
meterol and fluticasone in separate inhalers; the rest of
the patients used various medications (short acting b2 –
agonists alone, teophyllins, montelukast). Patients base-
line characteristics and demographics are shown in Table 1.
Lung function
Significant improvement in FEV1 was seen in all pa-
tients (76.27% to 86.94%, p<0.01) after 14 weeks of
treatment. Improvement in FEV1 was seen all ready af-
ter three weeks of treatment and then remained stable
during the follow – up period (Figure 1).
Significant improvement was also noticed in peak ex-
piratory flow (PEF) after 14 weeks (380.84 to 442.29
L/min, p<0.01). The improvement was noticed already
after 3 week of treatment (Figure 2).
Satisfaction with treatment
At the start of the study only 4.4% of patients were
very satisfied with previous treatment (grade 5); 24.4%
were satisfied (grade 4); 36.8% were moderately satisfied
(grade 3); 32% were unsatisfied (grade 2); and 2.4% were
very unsatisfied with previous treatment. Average grade
of satisfaction at the start of the study was 2.94. At the
end of the study 63.5% of patients were very satisfied
with the budesonide/formoterol in single inhaler (grade
5); 31.2% were satisfied (grade 4); 4.2% were moderately
satisfied (grade 3) and 1.1% of patients were unsatisfied
(grade 2) with the new treatment at the end of the study.
There were no very unsatisfied patients at the end of the
follow – up period. Average grade improved, from 2.94 to
4.56. This improvement was statistically significant (p<
0.01). (Figure 3)
At the start of the study 3.6 % of physicians were very
satisfied with previous treatment of their patients (grade
5); 15.3% were satisfied (grade 4); 35.5% were moder-
ately satisfied (grade 3); 31.9% were unsatisfied (grade
2); and 13.7% were very unsatisfied with previous treat-
ment. Average grade of satisfaction at the start of the
study was 2.60. At the end of the study 59.6% of physi-
cians were very satisfied with their patients’ treatment
(grade 5); 26.6% were satisfied (grade 4); 11.2% were
moderately satisfied (grade 3) and 2.7% of patients were
unsatisfied (grade 2) with the treatment at the end of the
study. There were no very unsatisfied (grade 1) physi-
cians at the end of the follow – up period. Average grade
improved, from 2.60 to 4.41. This improvement was sta-
tistically significant (p<0.01) (Figure 4).
Safety
Only small number of side effects was recorded dur-
ing the study period. Dysphonia was noticed in 8 patients
(3%); headache in 6 (2%); metorism in 5 (2%); tremor in 5
patients (2%); oral candidiasis in 2 patients (1%); tachy-
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TABLE 1
PATIENTS DEMOGRAPHIC AND BASELINE CHARACTERISTICS
Mean age (range) 40,8 y (11–76)
Previous asthma 225 (84%)
Newly diagnosed asthma 43 (16%)
Prestudy medication
Seretide 88 (39%)
fluticasone and salmeterol 16 (7%)
fluticasone 25 (11%)
budesonide 27 (12%)
other 69 (31%)
Frequency of symptoms
every day 145 (54,2%)
weekly 94 (35,2%)
monthly 29 (10,6%)
Asthma severity
mild 27 (10%)
moderate 214 (80%)
severe 27 (10%)
Mean FEV1 76,27 %
Mean PEF 380.84 L/min
Average grade of satisfaction with previous therapy
patients 2.94
physicians 2.60
76,27
85,66
87,62
86,19
86,94
70,00
72,00
74,00
76,00
78,00
80,00
82,00
84,00
86,00
88,00
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Visit 1 Visit 2 Visit 3 Visit 4 Visit 5
%
p<0.01
Fig. 1. Improvement in FEV1 after 14 weeks.
380,84
434,33 436,75 437,41 442,29
350,00
360,00
370,00
380,00
390,00
400,00
410,00
420,00
430,00
440,00
450,00
Visit 1 Visit 2 Visit 3 Visit 4 Visit 5
L
/m
in
p<0.01
Fig. 2. Improvement in PEF after 14 weeks.
cardia in 1 patient (0.3%); vomitus in 1 (0.3%); and rash
in 1 patient (0.3%).
Discussion
In this 14 – week, open – label study we tried to esti-
mate the efficacy and safety of fixed combination of
budesonide/formoterol in asthma patients with persis-
tent asthma. Our primary end point was improvement in
lung function. In all patients we noticed significant im-
provement in lung function measured by FEV1 and PEF
after 14 weeks of treatment. Thus, this improvement
was already noticed after three weeks of treatment. In
this study we also tried to estimate patient and, what is
rarely done, physicians satisfaction with their patients’
treatment. We found significant improvement in satis-
faction, both patients and physicians with budesonide/
formoterol fixed combination treatment compared with
previous therapy. Only small number of adverse events
was reported during the study.
Asthma treatment approach used in this study was in
accordance with previous studies which showed efficacy
of fixed combination and fixed dosing of budesonide/for-
moterol combination6,7,10.
Majority of patients in the study were patients with
moderate persistent asthma2, and small percentage of
our patients were those with other categories of persis-
tent asthma. In our study there were 10% of patients
with mild persistent asthma, which were also included in
the study, although, current guidelines do not recom-
mend inhaled corticosteroids and long – acting b2 – ago-
nist combination in the treatment of such patients. Thus,
all patients with mild asthma were not well controlled on
high doses of inhaled corticosteroid alone, so they were
included in the study.
We demonstrated in our study that budesonide/for-
moterol quickly improved lung function, already after
three weeks of treatment and than maintained this im-
provement throughout the study period. This result is
supported by several studies which showed that bude-
sonide/formoterol combination quickly gains asthma con-
trol in patients with mild, moderate and severe persis-
tent asthma10–12.
Interesting point was that 39% of patients were not
well controlled on fluticasone/salmetrol combination be-
fore entering the study. All those patients improved their
lung function and satisfaction with the budesonide/for-
moterol treatment after 14 weeks. However, this study
was not design to compare efficacy and safety of bude-
sonide/formoterol and fluticasone/salmeterol combina-
tion, although, this observation was in favor of SUND
study which showed better asthma control in patients
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Fig. 3. Patients satisfaction with the budesonide/formoterol treatment. (percentage of patients
in each group of satistfaction at each visit).
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Fig. 4. Physicians satisfaction with the budesonide/formoterol treatment. (percentage of physicians
in each group of satistfaction at each visit).
who were treated with budesonide/formoterol than flu-
ticasone/salmeterol14.
Budesonide/formoterol has rapid onset of action, even
within minutes15–17. This rapid onset of action may be
important factor for good compliance of patients to the
budesonide/formoterol, so this can partially explained
improvement in satisfaction of our patients with the
treatment compared with previous one.
Limitation of this study was that there was no control
group. We used as primary end point improvement in
lung function. Using only isolated parameters, like lung
function, for estimation of asthma control can overesti-
mate control of the disease18. Asthma control should not
only be estimated according to isolated parameters. It
should be estimated according to lung function, presence
of day and night symptoms, reliever usage, exacerbations
and presence of treatment adverse events2.
Budesonide/formoterol (Symbicort Turbuhaler®, As-
traZeneca) is en affective and well tolerated treatment
option for patients with persistent asthma. The ability to
administer both anti – inflammatory and bronchodila-
tory drugs in one inhaler improves adherence of patients.
Budesonide/formoterol fixed combination could be rea-
sonable choice for first line treatment in patients with
moderate to severe persistent asthma.
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U^INKOVITOST I SIGURNOST KOMBINCIJE BIDEZONIDA I FORMOTEROLA
U BOLESNIKA S ASTMOM
S A @ E T A K
Kombinacija budezonida i formoterola u jednom inhalatoru koristi se u bolesnika koji nemaju dobru kontrolu astme
uz inhalacijske kortikosteroide. Cilj ovog rada je procijeniti u~inkovitost i sigurnost fiksne kombinacije budezonida i
formoterola te procijeniti zadovoljstvo bolesnika i lije~nika navedenom terapijom. U studiju je uklju~eno ukupno 120
ispitanika. Svi bolesnici su koristili budezonid/formoterol dva puta na dan u ukupnoj dozi 640 mcg budezonida i 18 mcg
formoterola kroz tri tjedna. Bolesnici su pra}eni tijekom 14 tjedana u 5 posjeta. Na svakoj posjeti mjerena je plu}na
funkcija, bilje`eno prisustvo nuspojava, te su bolesnici i lije~nici ispunjavali upitnik o zadovoljstvu lije~enjem. Tijekom
pra}enja na|eno je zna~ajno pobolj{anje u plu}noj funkciju (FEV1 i PEF). Tako|er, na kraju studije zna~ajno ve}e za-
dovoljstvo lije~enjem pokazano je i medu ispitanicima i medu lije~nicima. U kona~nici, budezonid i formoterol u jednom
inhalatoru zna~ajno pobolj{ava plu}nu funkciju, te zadovoljstvo lije~enjem u bolesnika s astmom.
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